PMID- 25520861
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141218
LR  - 20200930
IS  - 2156-6976 (Print)
IS  - 2156-6976 (Electronic)
IS  - 2156-6976 (Linking)
VI  - 4
IP  - 6
DP  - 2014
TI  - ABCG2 regulated by MAPK pathways is associated with cancer progression in 
      laryngeal squamous cell carcinoma.
PG  - 698-709
AB  - ATP-binding cassette, subfamily G, member 2 (ABCG2) overexpression has been 
      associated with multidrug resistance and cancer progression by promoting 
      proliferation and/or suppressing apoptosis, but how this process happens remains 
      to be determined. In this study, the roles and the mechanisms of ABCG2 in the 
      progression of Laryngeal squamous cell carcinoma (LSCC) were investigated. We 
      found that introduction of ABCG2 siRNA into Hep-2 and Hep-2T cells significantly 
      enhanced the intracellular accumulation of mitoxantrone (MX). Down-regulation of 
      ABCG2 by transient RNAi inhibited cell proliferation and blocked cell cycle 
      progression by regulating the expression of cyclin D3 and p21 Cip1. ABCG2 silence 
      also induced cell apoptosis by regulating the expression of surviving, bcl-2 and 
      the cleavage of poly (ADP-ribose) polymerase (PARP) in Hep-2 and Hep-2T cells. 
      ABCG2-specific inhibitor, fumitremorgin C (FTC), and mitogen-activated protein 
      kinase (MAPK) pathway inhibitor, U0126, inhibited cell proliferation and promoted 
      cell apoptosis by degrading endogenous ABCG2 in Hep-2T cells. Furthermore, 
      inhibition of MAPK pathway by U0126 enhanced anti-cancer effects of MX in vivo. 
      In conclusion, suppression of ABCG2 inhibits the procession of LSCC tumor growth 
      by regulating cell proliferation and apoptosis. Our data also provide more 
      evidence for the importance of the MAPK pathway as a suitable therapeutic target 
      for LSCC.
FAU - Xie, Jin
AU  - Xie J
AD  - Department of Otolaryngology-Head and Neck Surgery, Shanghai Jiao Tong University 
      Affiliated First People's Hospital Shanghai 200080, China.
FAU - Jin, Bin
AU  - Jin B
AD  - Department of Otolaryngology-Head and Neck Surgery, Shanghai Jiao Tong University 
      Affiliated First People's Hospital Shanghai 200080, China.
FAU - Li, Da-Wei
AU  - Li DW
AD  - Department of Otolaryngology-Head and Neck Surgery, Shanghai Jiao Tong University 
      Affiliated Sixth People's Hospital Shanghai 200233, China.
FAU - Shen, Bin
AU  - Shen B
AD  - Department of Otolaryngology-Head and Neck Surgery, Shanghai Jiao Tong University 
      Affiliated First People's Hospital Shanghai 200080, China.
FAU - Cong, Ning
AU  - Cong N
AD  - Department of Otolaryngology-Head and Neck Surgery, Shanghai Jiao Tong University 
      Affiliated First People's Hospital Shanghai 200080, China.
FAU - Zhang, Tian-Zhen
AU  - Zhang TZ
AD  - Department of Otolaryngology-Head and Neck Surgery, Shanghai Jiao Tong University 
      Affiliated First People's Hospital Shanghai 200080, China.
FAU - Dong, Pin
AU  - Dong P
AD  - Department of Otolaryngology-Head and Neck Surgery, Shanghai Jiao Tong University 
      Affiliated First People's Hospital Shanghai 200080, China.
LA  - eng
PT  - Journal Article
DEP - 20141119
PL  - United States
TA  - Am J Cancer Res
JT  - American journal of cancer research
JID - 101549944
PMC - PMC4266705
OTO - NOTNLM
OT  - BCG2
OT  - MAPK pathway
OT  - fumitremorgin C
OT  - laryngeal squamous cell carcinoma
OT  - mitoxantrone
EDAT- 2014/12/19 06:00
MHDA- 2014/12/19 06:01
PMCR- 2014/11/19
CRDT- 2014/12/19 06:00
PHST- 2014/08/06 00:00 [received]
PHST- 2014/09/30 00:00 [accepted]
PHST- 2014/12/19 06:00 [entrez]
PHST- 2014/12/19 06:00 [pubmed]
PHST- 2014/12/19 06:01 [medline]
PHST- 2014/11/19 00:00 [pmc-release]
PST - epublish
SO  - Am J Cancer Res. 2014 Nov 19;4(6):698-709. eCollection 2014.